drugset / Trial / NCT02788240

To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

NCT02788240

RandomizedParallel-groupDouble-blindTreatment

Summary

All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).

Timeline

Start
2016-05-01
Primary completion
2017-07-15
Completion
2017-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic
Background Albumin Protein / enzyme biologic 20 %
Background Imepenem Unknown
Background Meropenem Small molecule
Background Terlipressin Peptide 1 mg
Background Terlipressin Peptide 4 mg

Indications